 Brigitte Frohnert
Concepts (280)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetes Mellitus, Type 1 | 47 | 2026 | 3793 | 3.420 |
Why?
| | Islets of Langerhans | 20 | 2026 | 809 | 2.660 |
Why?
| | Autoimmunity | 22 | 2026 | 908 | 2.240 |
Why?
| | Autoantibodies | 29 | 2025 | 1466 | 1.630 |
Why?
| | Celiac Disease | 5 | 2022 | 295 | 0.890 |
Why?
| | Genetic Predisposition to Disease | 11 | 2023 | 2366 | 0.870 |
Why?
| | Protein Carbonylation | 3 | 2015 | 56 | 0.840 |
Why?
| | Insulins | 1 | 2023 | 37 | 0.760 |
Why?
| | Insulin Resistance | 6 | 2013 | 1221 | 0.730 |
Why?
| | Oxidative Stress | 3 | 2013 | 1327 | 0.710 |
Why?
| | Child, Preschool | 28 | 2026 | 11511 | 0.620 |
Why?
| | Adipocytes | 4 | 2013 | 220 | 0.610 |
Why?
| | Child | 42 | 2026 | 22390 | 0.600 |
Why?
| | Insulin Infusion Systems | 3 | 2023 | 480 | 0.580 |
Why?
| | Bone Density | 3 | 2020 | 496 | 0.550 |
Why?
| | HLA-D Antigens | 1 | 2017 | 30 | 0.530 |
Why?
| | Insulin | 9 | 2023 | 2472 | 0.530 |
Why?
| | Disease Progression | 11 | 2026 | 2808 | 0.490 |
Why?
| | Infusions, Subcutaneous | 1 | 2015 | 23 | 0.470 |
Why?
| | Fatty Acids, Nonesterified | 2 | 2013 | 158 | 0.460 |
Why?
| | Equipment Failure | 1 | 2015 | 112 | 0.450 |
Why?
| | Prospective Studies | 15 | 2026 | 7805 | 0.440 |
Why?
| | Infant | 18 | 2023 | 9820 | 0.440 |
Why?
| | Models, Genetic | 1 | 2017 | 587 | 0.430 |
Why?
| | Adolescent | 28 | 2026 | 22116 | 0.430 |
Why?
| | Blood Glucose | 5 | 2026 | 2286 | 0.420 |
Why?
| | Blood Glucose Self-Monitoring | 4 | 2025 | 713 | 0.410 |
Why?
| | Genotype | 7 | 2022 | 1854 | 0.410 |
Why?
| | Lipid Peroxidation | 1 | 2013 | 150 | 0.380 |
Why?
| | Hypoglycemic Agents | 4 | 2023 | 1380 | 0.380 |
Why?
| | Polymorphism, Single Nucleotide | 4 | 2020 | 2122 | 0.380 |
Why?
| | Humans | 62 | 2026 | 141284 | 0.370 |
Why?
| | DNA Methylation | 3 | 2023 | 643 | 0.360 |
Why?
| | Adiposity | 3 | 2013 | 520 | 0.360 |
Why?
| | Subcutaneous Fat, Abdominal | 1 | 2011 | 14 | 0.350 |
Why?
| | Biomarkers | 5 | 2023 | 4180 | 0.340 |
Why?
| | Fasting | 2 | 2010 | 283 | 0.330 |
Why?
| | Case-Control Studies | 10 | 2023 | 3577 | 0.320 |
Why?
| | Obesity | 3 | 2013 | 3007 | 0.320 |
Why?
| | Metabolomics | 1 | 2015 | 702 | 0.320 |
Why?
| | Male | 37 | 2026 | 70140 | 0.300 |
Why?
| | Female | 38 | 2026 | 75814 | 0.290 |
Why?
| | Protein Tyrosine Phosphatase, Non-Receptor Type 22 | 2 | 2019 | 48 | 0.280 |
Why?
| | Cystic Fibrosis | 3 | 2012 | 1124 | 0.250 |
Why?
| | Mitochondria | 1 | 2013 | 962 | 0.250 |
Why?
| | Inflammation | 2 | 2017 | 2840 | 0.240 |
Why?
| | Macrophages | 1 | 2013 | 1478 | 0.240 |
Why?
| | Diabetes Mellitus, Type 2 | 5 | 2023 | 2529 | 0.220 |
Why?
| | Kaplan-Meier Estimate | 2 | 2017 | 910 | 0.220 |
Why?
| | Oxylipins | 2 | 2023 | 41 | 0.220 |
Why?
| | HLA-DR4 Antigen | 3 | 2021 | 77 | 0.210 |
Why?
| | HLA-DR3 Antigen | 3 | 2021 | 76 | 0.210 |
Why?
| | Cardiovascular Diseases | 2 | 2013 | 2091 | 0.210 |
Why?
| | Membrane Transport Proteins | 3 | 1999 | 153 | 0.200 |
Why?
| | Carrier Proteins | 4 | 2000 | 738 | 0.200 |
Why?
| | GTP-Binding Proteins | 2 | 2021 | 151 | 0.190 |
Why?
| | HLA-DR Antigens | 3 | 2022 | 222 | 0.190 |
Why?
| | Transglutaminases | 2 | 2021 | 156 | 0.190 |
Why?
| | Young Adult | 9 | 2026 | 13727 | 0.190 |
Why?
| | Vitamin D | 1 | 2026 | 401 | 0.190 |
Why?
| | Technology | 1 | 2023 | 95 | 0.190 |
Why?
| | Glutathione Transferase | 2 | 2013 | 99 | 0.190 |
Why?
| | Growth Charts | 1 | 2022 | 15 | 0.180 |
Why?
| | Glucose Tolerance Test | 3 | 2018 | 367 | 0.180 |
Why?
| | Risk Factors | 11 | 2025 | 10490 | 0.180 |
Why?
| | Longitudinal Studies | 5 | 2022 | 2929 | 0.170 |
Why?
| | Body Height | 1 | 2022 | 200 | 0.170 |
Why?
| | Diet, Ketogenic | 1 | 2021 | 36 | 0.170 |
Why?
| | Diet, Carbohydrate-Restricted | 1 | 2021 | 37 | 0.170 |
Why?
| | Prediabetic State | 1 | 2023 | 251 | 0.160 |
Why?
| | Cohort Studies | 6 | 2026 | 5809 | 0.160 |
Why?
| | Glutamate Decarboxylase | 4 | 2022 | 166 | 0.160 |
Why?
| | Mannose | 1 | 2019 | 23 | 0.160 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2026 | 908 | 0.160 |
Why?
| | Adenosine Diphosphate | 1 | 2019 | 80 | 0.150 |
Why?
| | Inservice Training | 1 | 2020 | 119 | 0.150 |
Why?
| | Glucose Intolerance | 2 | 2010 | 146 | 0.150 |
Why?
| | Butyrates | 1 | 2019 | 60 | 0.150 |
Why?
| | Osteoporotic Fractures | 1 | 2020 | 61 | 0.150 |
Why?
| | Insulin-Secreting Cells | 1 | 2023 | 382 | 0.140 |
Why?
| | Fibrinogen | 1 | 2019 | 179 | 0.140 |
Why?
| | Membrane Proteins | 3 | 1999 | 1144 | 0.140 |
Why?
| | Ascorbic Acid | 1 | 2019 | 180 | 0.140 |
Why?
| | Fatty Acids | 3 | 2000 | 446 | 0.140 |
Why?
| | Thiazolidinediones | 1 | 1999 | 134 | 0.140 |
Why?
| | Mentors | 1 | 2020 | 213 | 0.140 |
Why?
| | Mammals | 1 | 2000 | 284 | 0.140 |
Why?
| | Mass Spectrometry | 1 | 2021 | 734 | 0.140 |
Why?
| | Cross-Sectional Studies | 5 | 2020 | 5653 | 0.140 |
Why?
| | Interprofessional Relations | 1 | 2020 | 282 | 0.140 |
Why?
| | Discriminant Analysis | 1 | 2017 | 37 | 0.130 |
Why?
| | Triglycerides | 1 | 2000 | 510 | 0.130 |
Why?
| | Mentoring | 1 | 2020 | 150 | 0.130 |
Why?
| | Receptors, Cytoplasmic and Nuclear | 1 | 1999 | 207 | 0.130 |
Why?
| | Absorptiometry, Photon | 2 | 2020 | 266 | 0.130 |
Why?
| | Osteoporosis | 1 | 2020 | 242 | 0.130 |
Why?
| | Polymorphism, Genetic | 1 | 2019 | 619 | 0.130 |
Why?
| | Models, Statistical | 1 | 2021 | 669 | 0.130 |
Why?
| | Health Care Costs | 1 | 2020 | 417 | 0.120 |
Why?
| | Family Health | 1 | 2017 | 194 | 0.120 |
Why?
| | HLA-DQ Antigens | 1 | 2017 | 173 | 0.120 |
Why?
| | Infant, Newborn | 5 | 2022 | 6270 | 0.120 |
Why?
| | History, 21st Century | 1 | 2017 | 218 | 0.120 |
Why?
| | Organelle Biogenesis | 1 | 2015 | 15 | 0.120 |
Why?
| | Disease-Free Survival | 1 | 2017 | 713 | 0.120 |
Why?
| | Subcutaneous Fat | 1 | 2015 | 81 | 0.110 |
Why?
| | Age of Onset | 1 | 2017 | 536 | 0.110 |
Why?
| | Proteins | 1 | 2021 | 1007 | 0.110 |
Why?
| | Guidelines as Topic | 1 | 2017 | 269 | 0.110 |
Why?
| | Genetic Testing | 1 | 2018 | 462 | 0.110 |
Why?
| | Mass Screening | 2 | 2021 | 1309 | 0.110 |
Why?
| | Hypoglycemia | 1 | 2020 | 470 | 0.110 |
Why?
| | Proteomics | 1 | 2021 | 1137 | 0.110 |
Why?
| | Intestinal Mucosa | 1 | 2000 | 630 | 0.110 |
Why?
| | DNA-Binding Proteins | 2 | 2015 | 1483 | 0.110 |
Why?
| | Gastric Bypass | 1 | 2015 | 119 | 0.110 |
Why?
| | Aldehyde Reductase | 1 | 2013 | 29 | 0.100 |
Why?
| | Body Mass Index | 2 | 2013 | 2390 | 0.100 |
Why?
| | Transcription Factors | 2 | 2015 | 1706 | 0.100 |
Why?
| | Adult | 8 | 2026 | 39319 | 0.100 |
Why?
| | Growth Disorders | 1 | 2013 | 87 | 0.100 |
Why?
| | Muscle Cells | 1 | 2013 | 42 | 0.100 |
Why?
| | Age Factors | 3 | 2020 | 3295 | 0.100 |
Why?
| | Ultrasonography, Doppler | 1 | 2013 | 122 | 0.100 |
Why?
| | Aldehydes | 1 | 2013 | 146 | 0.100 |
Why?
| | Autoimmune Diseases | 1 | 2017 | 463 | 0.100 |
Why?
| | Human Growth Hormone | 1 | 2012 | 46 | 0.090 |
Why?
| | Models, Biological | 1 | 2019 | 1810 | 0.090 |
Why?
| | Consensus | 2 | 2024 | 538 | 0.090 |
Why?
| | Glutathione | 1 | 2013 | 361 | 0.090 |
Why?
| | Aldehyde Dehydrogenase, Mitochondrial | 1 | 2011 | 23 | 0.090 |
Why?
| | Aldehyde Oxidoreductases | 1 | 2011 | 27 | 0.090 |
Why?
| | Intra-Abdominal Fat | 1 | 2011 | 89 | 0.080 |
Why?
| | Aldehyde Dehydrogenase | 1 | 2011 | 100 | 0.080 |
Why?
| | Gene Expression Regulation, Enzymologic | 1 | 2011 | 269 | 0.080 |
Why?
| | Sensitivity and Specificity | 3 | 2022 | 1973 | 0.080 |
Why?
| | United States | 4 | 2022 | 15298 | 0.080 |
Why?
| | Diabetic Ketoacidosis | 2 | 2024 | 208 | 0.080 |
Why?
| | Time Factors | 2 | 2017 | 6951 | 0.080 |
Why?
| | Survivors | 1 | 2012 | 501 | 0.070 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2013 | 1220 | 0.070 |
Why?
| | Glucose | 1 | 2013 | 1027 | 0.070 |
Why?
| | RNA, Messenger | 2 | 2015 | 2815 | 0.070 |
Why?
| | Predictive Value of Tests | 3 | 2019 | 2069 | 0.070 |
Why?
| | Obesity, Morbid | 1 | 2011 | 277 | 0.060 |
Why?
| | Genetic Association Studies | 2 | 2020 | 373 | 0.060 |
Why?
| | Hyperglycemia | 1 | 2010 | 365 | 0.060 |
Why?
| | Overweight | 1 | 2011 | 589 | 0.060 |
Why?
| | Colorado | 3 | 2023 | 4599 | 0.060 |
Why?
| | Risk Assessment | 3 | 2020 | 3522 | 0.060 |
Why?
| | Fatty Acid Transport Proteins | 3 | 1999 | 19 | 0.060 |
Why?
| | Follow-Up Studies | 3 | 2021 | 5222 | 0.060 |
Why?
| | Diabetes Mellitus | 1 | 2012 | 1078 | 0.050 |
Why?
| | GTPase-Activating Proteins | 1 | 2023 | 85 | 0.050 |
Why?
| | CpG Islands | 1 | 2023 | 164 | 0.050 |
Why?
| | Finland | 1 | 2022 | 81 | 0.050 |
Why?
| | Seroepidemiologic Studies | 1 | 2023 | 170 | 0.050 |
Why?
| | Prognosis | 3 | 2018 | 4080 | 0.050 |
Why?
| | Germany | 1 | 2022 | 132 | 0.050 |
Why?
| | Mice | 3 | 2013 | 17969 | 0.040 |
Why?
| | Diagnostic Techniques, Radioisotope | 1 | 2021 | 9 | 0.040 |
Why?
| | Linoleic Acid | 1 | 2021 | 43 | 0.040 |
Why?
| | Receptor-Like Protein Tyrosine Phosphatases, Class 8 | 1 | 2021 | 54 | 0.040 |
Why?
| | Immunoglobulin D | 1 | 2021 | 30 | 0.040 |
Why?
| | Arachidonic Acid | 1 | 2021 | 107 | 0.040 |
Why?
| | Serologic Tests | 1 | 2021 | 54 | 0.040 |
Why?
| | Perception | 1 | 2023 | 375 | 0.040 |
Why?
| | Animals | 5 | 2013 | 37328 | 0.040 |
Why?
| | Electrochemical Techniques | 1 | 2021 | 53 | 0.040 |
Why?
| | Markov Chains | 1 | 2021 | 123 | 0.040 |
Why?
| | Docosahexaenoic Acids | 1 | 2021 | 85 | 0.040 |
Why?
| | Iodide Peroxidase | 1 | 2020 | 34 | 0.040 |
Why?
| | Asymptomatic Diseases | 1 | 2021 | 98 | 0.040 |
Why?
| | Glutens | 1 | 2020 | 59 | 0.040 |
Why?
| | Absorption | 1 | 2000 | 60 | 0.040 |
Why?
| | Transfection | 2 | 1999 | 932 | 0.040 |
Why?
| | Coenzyme A Ligases | 1 | 1999 | 15 | 0.040 |
Why?
| | Quality-Adjusted Life Years | 1 | 2020 | 112 | 0.040 |
Why?
| | Peroxidase | 1 | 2020 | 174 | 0.040 |
Why?
| | Femur Neck | 1 | 2020 | 63 | 0.040 |
Why?
| | Whole Genome Sequencing | 1 | 2020 | 170 | 0.040 |
Why?
| | Diffusion | 1 | 2000 | 121 | 0.040 |
Why?
| | Nerve Tissue Proteins | 1 | 2023 | 605 | 0.040 |
Why?
| | Immunoglobulin M | 1 | 2021 | 284 | 0.040 |
Why?
| | Immunoglobulin A | 1 | 2021 | 214 | 0.040 |
Why?
| | Clinical Protocols | 1 | 2021 | 273 | 0.040 |
Why?
| | Costs and Cost Analysis | 1 | 2020 | 219 | 0.040 |
Why?
| | Chromans | 1 | 1999 | 25 | 0.040 |
Why?
| | Retinoid X Receptors | 1 | 1999 | 38 | 0.040 |
Why?
| | Immunoglobulin E | 1 | 2021 | 319 | 0.040 |
Why?
| | Receptors, Retinoic Acid | 1 | 1999 | 41 | 0.040 |
Why?
| | Physicians, Women | 1 | 2020 | 87 | 0.040 |
Why?
| | Early Diagnosis | 1 | 2020 | 243 | 0.040 |
Why?
| | Chromatography, High Pressure Liquid | 1 | 2021 | 589 | 0.040 |
Why?
| | Oleic Acid | 1 | 1999 | 42 | 0.040 |
Why?
| | 3T3 Cells | 1 | 1999 | 152 | 0.040 |
Why?
| | Gene Frequency | 1 | 2020 | 488 | 0.040 |
Why?
| | Dimerization | 1 | 1999 | 196 | 0.040 |
Why?
| | Antibodies, Viral | 1 | 2023 | 654 | 0.040 |
Why?
| | Biological Transport | 1 | 2000 | 409 | 0.040 |
Why?
| | Thiazoles | 1 | 1999 | 133 | 0.040 |
Why?
| | Base Sequence | 2 | 1999 | 2170 | 0.040 |
Why?
| | Regulatory Sequences, Nucleic Acid | 1 | 1998 | 93 | 0.040 |
Why?
| | Interleukins | 1 | 2020 | 250 | 0.040 |
Why?
| | Peer Group | 1 | 2020 | 248 | 0.030 |
Why?
| | Minority Groups | 1 | 2020 | 278 | 0.030 |
Why?
| | Tretinoin | 1 | 1999 | 121 | 0.030 |
Why?
| | Nutritional Status | 1 | 2021 | 357 | 0.030 |
Why?
| | Career Choice | 1 | 2020 | 233 | 0.030 |
Why?
| | Pelvic Bones | 1 | 2020 | 129 | 0.030 |
Why?
| | Postmenopause | 1 | 2020 | 369 | 0.030 |
Why?
| | Lumbar Vertebrae | 1 | 2020 | 252 | 0.030 |
Why?
| | Tandem Mass Spectrometry | 1 | 2021 | 565 | 0.030 |
Why?
| | Quantitative Trait Loci | 1 | 2020 | 364 | 0.030 |
Why?
| | Universities | 1 | 2020 | 450 | 0.030 |
Why?
| | Molecular Sequence Data | 2 | 1999 | 2911 | 0.030 |
Why?
| | Collagen | 1 | 2020 | 452 | 0.030 |
Why?
| | ROC Curve | 1 | 2019 | 594 | 0.030 |
Why?
| | Social Media | 1 | 2020 | 160 | 0.030 |
Why?
| | Cost-Benefit Analysis | 1 | 2020 | 612 | 0.030 |
Why?
| | Neoplasms | 1 | 2012 | 2731 | 0.030 |
Why?
| | Gestational Age | 1 | 2020 | 952 | 0.030 |
Why?
| | Neoplasm Proteins | 1 | 2020 | 435 | 0.030 |
Why?
| | Immunoglobulin G | 1 | 2021 | 882 | 0.030 |
Why?
| | Occupational Exposure | 1 | 2020 | 346 | 0.030 |
Why?
| | Anxiety | 1 | 2023 | 1078 | 0.030 |
Why?
| | Nuclear Respiratory Factor 1 | 1 | 2015 | 3 | 0.030 |
Why?
| | Social Support | 1 | 2020 | 629 | 0.030 |
Why?
| | Societies, Medical | 1 | 2020 | 859 | 0.030 |
Why?
| | Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha | 1 | 2015 | 40 | 0.030 |
Why?
| | Patient Education as Topic | 1 | 2021 | 771 | 0.030 |
Why?
| | Up-Regulation | 1 | 1999 | 851 | 0.030 |
Why?
| | Insulin Antibodies | 1 | 2016 | 103 | 0.030 |
Why?
| | Electron Transport Complex IV | 1 | 2015 | 61 | 0.030 |
Why?
| | Prevalence | 1 | 2023 | 2795 | 0.030 |
Why?
| | Practice Guidelines as Topic | 1 | 2023 | 1546 | 0.030 |
Why?
| | C-Reactive Protein | 1 | 2018 | 416 | 0.030 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 374 | 0.030 |
Why?
| | Risk | 1 | 2018 | 903 | 0.030 |
Why?
| | Coronavirus Infections | 1 | 2020 | 370 | 0.030 |
Why?
| | Epigenesis, Genetic | 1 | 2020 | 661 | 0.030 |
Why?
| | Nitric Oxide Synthase | 1 | 2015 | 241 | 0.030 |
Why?
| | Chronic Disease | 1 | 2021 | 1807 | 0.030 |
Why?
| | Parents | 1 | 2023 | 1439 | 0.030 |
Why?
| | Proportional Hazards Models | 1 | 2018 | 1268 | 0.030 |
Why?
| | Sex Factors | 1 | 2020 | 2055 | 0.030 |
Why?
| | Family | 1 | 2018 | 677 | 0.030 |
Why?
| | Mitochondrial Proteins | 1 | 2015 | 259 | 0.030 |
Why?
| | Reproducibility of Results | 1 | 2021 | 3345 | 0.020 |
Why?
| | Multivariate Analysis | 1 | 2016 | 1505 | 0.020 |
Why?
| | DNA | 1 | 1999 | 1440 | 0.020 |
Why?
| | Glucose Clamp Technique | 1 | 2012 | 197 | 0.020 |
Why?
| | Pandemics | 1 | 2020 | 1655 | 0.020 |
Why?
| | Physicians | 1 | 2020 | 930 | 0.020 |
Why?
| | Cell Differentiation | 1 | 1999 | 1983 | 0.020 |
Why?
| | Treatment Outcome | 1 | 2026 | 11216 | 0.020 |
Why?
| | Haplotypes | 1 | 2012 | 490 | 0.020 |
Why?
| | Minnesota | 1 | 2010 | 168 | 0.020 |
Why?
| | Middle Aged | 3 | 2020 | 34658 | 0.020 |
Why?
| | Incidence | 1 | 2017 | 2809 | 0.020 |
Why?
| | Cytokines | 1 | 2017 | 2079 | 0.020 |
Why?
| | Fatty Liver | 1 | 2009 | 237 | 0.020 |
Why?
| | Polycystic Ovary Syndrome | 1 | 2009 | 180 | 0.020 |
Why?
| | Models, Theoretical | 1 | 2009 | 582 | 0.010 |
Why?
| | Metabolic Syndrome | 1 | 2009 | 352 | 0.010 |
Why?
| | Sequence Analysis | 1 | 1999 | 35 | 0.010 |
Why?
| | Aged | 1 | 2020 | 24836 | 0.010 |
Why?
| | COS Cells | 1 | 1999 | 179 | 0.010 |
Why?
| | Cloning, Molecular | 1 | 1998 | 531 | 0.010 |
Why?
| | In Situ Hybridization, Fluorescence | 1 | 1998 | 310 | 0.010 |
Why?
| | Introns | 1 | 1998 | 253 | 0.010 |
Why?
| | Chromosome Mapping | 1 | 1998 | 502 | 0.010 |
Why?
| | Exons | 1 | 1998 | 352 | 0.010 |
Why?
| | Alternative Splicing | 1 | 1998 | 232 | 0.010 |
Why?
| | Sequence Analysis, DNA | 1 | 1998 | 815 | 0.010 |
Why?
| | Promoter Regions, Genetic | 1 | 1998 | 1244 | 0.010 |
Why?
| | Retrospective Studies | 1 | 2010 | 16447 | 0.010 |
Why?
| | Protein Binding | 1 | 1998 | 2233 | 0.010 |
Why?
| | Transcription, Genetic | 1 | 1998 | 1486 | 0.010 |
Why?
| | Gene Expression Regulation | 1 | 1998 | 2600 | 0.000 |
Why?
|
|
Frohnert's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|